What Is an Epigenetic Age Test? The Science Behind Biological Age Tracking

If you’ve been on a GLP-1 drug for a few months and the scale is moving, you might wonder: am I getting healthier, or am I just lighter? It’s not the same question.

Weight is easy to measure. Biological aging is harder — but it’s what actually determines whether the weight loss is translating into better long-term health, or whether caloric restriction, muscle loss, and the metabolic stress of rapid body composition change are accelerating your cellular wear.

Epigenetic age testing is the most validated way to measure that outside a research lab.

Your DNA Has a Clock Inside It

Every cell in your body contains roughly 3 billion base pairs of DNA, but your cells don’t all behave the same way. What controls gene expression — which genes get read, which stay silent — is in large part determined by chemical tags called methyl groups that attach to specific positions on your DNA.

These methylation patterns aren’t random. They shift predictably as you age, across hundreds of specific genomic sites, in a trajectory researchers have been able to map and use as a molecular clock. The field is called epigenetic age estimation, and it has produced some of the most robust biomarkers in aging science.

How Epigenetic Aging Clocks Work

In 2013, biostatistician Steve Horvath published what became one of the most-cited papers in aging biology: an epigenetic clock built from 353 CpG sites (cytosine-phosphate-guanine dinucleotides — the positions in your genome where methylation most frequently occurs). Trained on 8,000 samples from 51 tissue types, it predicted chronological age with an R² of 0.97.

(Horvath S. Genome Biology 2013; PMID 24138928)

The core principle: methylation at specific sites follows a predictable trajectory from birth onward. By reading those sites, you can estimate how old a cell’s biology is acting — independently of calendar time. Deviations from the expected pattern are the measure of biological age acceleration or deceleration.

Since 2013, the field has evolved through three generations of clocks:

First-Generation Clocks: Trained on Chronological Age

Horvath (2013) and Hannum (2013) were trained to predict chronological age from methylation data. Their utility comes from the deviations: if your clock reads 52 and you’re 45, that 7-year “acceleration” is the signal worth paying attention to.

Second-Generation Clocks: Trained on Health Outcomes

PhenoAge (Levine et al., 2018) was trained on a composite of nine phenotypic biomarkers associated with mortality — albumin, creatinine, glucose, CRP, lymphocyte percent, mean cell volume, alkaline phosphatase, white blood cell count, and chronological age. PhenoAge acceleration predicts all-cause mortality better than first-generation clocks.

(Levine ME et al. Aging 2018; PMID 29676998)

GrimAge (Lu et al., 2019) was trained directly on time-to-death, incorporating 10 plasma protein surrogates in a longitudinal cohort. It is currently among the strongest methylation-based mortality predictors in the published literature.

(Lu AT et al. Aging 2019; PMID 30669119)

Third-Generation Clocks: Measuring the Rate of Aging

DunedinPACE (Belsky et al., 2022) is the most conceptually distinct development. Unlike the clocks above — which give you a biological age snapshot — DunedinPACE measures your biological pace of aging: how fast your cells are currently aging.

The distinction matters for tracking interventions. A GrimAge reading gives you a snapshot. DunedinPACE tells you whether your aging trajectory is accelerating (score above 1.0), neutral (1.0), or slowing (below 1.0). For someone asking “is what I’m doing working?” — it’s the right tool.

(Belsky DW et al. eLife 2022; PMID 35184856)

What TruDiagnostic Measures

TruDiagnostic offers epigenetic age analysis through their TruAge platform. Their TruAge COMPLETE panel analyzes approximately 950,000 CpG sites — substantially broader coverage than most academic validation panels — and reports multiple clocks simultaneously:

• Horvath Age (intrinsic and extrinsic versions)
• PhenoAge and PhenoAge Acceleration
• GrimAge 2.0 and GrimAge Age Acceleration
• DunedinPACE (pace of aging)
• TelomerAge (telomere length integrated into the biological age estimate)

The test uses a blood sample (finger prick or standard draw). Results arrive via an online dashboard. Pricing is approximately $229 for the full panel as of this writing — verify current pricing at TruDiagnostic’s site.

(Disclosure: links to TruDiagnostic on this site may be affiliate links — we earn a commission at no cost to you. This does not affect editorial independence.)

The GLP-1 and Epigenetic Aging Connection

This is an active research area. Here is what the published data shows — and what it doesn’t.

Obesity and metabolic dysfunction are associated with epigenetic age acceleration. Multiple observational studies have documented that individuals with elevated BMI, insulin resistance, and chronic inflammation show accelerated biological aging across multiple clock measures.

GLP-1 drugs produce significant metabolic changes — reductions in body weight, visceral fat, systemic inflammation, and glucose variability — that are hypothesized to influence epigenetic aging trajectories.

One published study has directly measured this. Corley et al. (2026) in Nature Communications found that semaglutide treatment was associated with a 9% slowing of DunedinPACE over 24 weeks.

(Corley MJ et al. Nature Communications 2026; PMID 40791720)

The essential caveat: This study was conducted specifically in HIV-positive adults with lipohypertrophy — a population with elevated baseline inflammatory burden and accelerated epigenetic aging relative to the general population. The finding is real and significant. It cannot be directly extrapolated to the general GLP-1 user. Other populations may show different magnitudes of effect, or no effect.

What this means practically: A baseline TruAge test before starting GLP-1 therapy and a follow-up 12–18 months later could give you personal data on whether your biological aging trajectory shifted. This is an n=1 experiment, not a clinical trial. But for anyone already inclined to quantify their health, it’s one of the few data points that can answer “is this working at a cellular level?”

Interpreting Your Results

DunedinPACE: Expressed as a decimal (e.g., 0.87 or 1.12). Below 1.0 = aging slower than the reference average; above 1.0 = faster. The score reflects current trajectory, not a fixed state — the same person can shift this number meaningfully over 12–18 months with sustained changes.

GrimAge Age Acceleration: GrimAge estimate minus chronological age. Negative = favorable. Positive = worth discussing with a physician in the context of your overall health picture.

PhenoAge Acceleration: Same interpretation. A negative score means your biology is tracking closer to a younger person’s phenotypic health profile.

What the clocks don’t tell you: They don’t identify causes. An elevated GrimAge can reflect years of smoking, poor sleep, chronic stress, high-inflammatory diet — or all four. The test gives you a biological signal. It cannot pinpoint the source or prescribe a fix.

Limitations to Know Before Testing

Intra-individual variability. Methylation measurements have day-to-day and sample-quality variation. A single result is an estimate within confidence intervals, not an exact number.

Reference population dependence. Clock scores are relative to a reference cohort used during training. Different clocks can give different absolute readings for the same person because they were trained on different populations.

Intervention responsiveness varies by clock. DunedinPACE has shown responsiveness to specific interventions in clinical trials; GrimAge and PhenoAge are less well characterized for how quickly they respond to typical lifestyle changes.

Not a medical test. These are research-grade biomarkers. Decisions about medications, supplements, or clinical care should be made with a licensed physician.

The Bottom Line

Chronological age is the least interesting thing about how your body is aging. Epigenetic clocks — particularly DunedinPACE — give you a more meaningful signal: is your biology running ahead of schedule, behind it, or right on time?

For GLP-1 users especially, that question has direct relevance. You’re losing weight, possibly significant amounts. GLP-1 drugs cause measurable lean mass loss — clinical trial data shows 40–45% of weight lost during semaglutide therapy comes from lean tissue. Are you also losing muscle in a way that’s accelerating your biological age? Or is the reduction in visceral fat and inflammation slowing it? The research is early, but the tools to measure it personally are available now.

A baseline before you start, a follow-up 12–18 months in. That’s the minimum data set for a meaningful answer.

Check TruDiagnostic pricing and order a TruAge COMPLETE test →

For readers researching the broader GLP-1 optimization landscape — including the published literature on growth hormone secretagogues and body composition — PeptidesOptimized provides COA-verified research compounds and educational documentation on the peer-reviewed science behind them.

Citations

[1] Horvath S. “DNA methylation age of human tissues and cell types.” Genome Biology 2013;14(10):R115. PMID 24138928

[2] Levine ME et al. “An epigenetic biomarker of aging for lifespan and healthspan.” Aging 2018;10(4):573–591. PMID 29676998

[3] Lu AT et al. “DNA methylation GrimAge strongly predicts lifespan and healthspan.” Aging 2019;11(2):303–327. PMID 30669119

[4] Belsky DW et al. “DunedinPACE, a DNA methylation biomarker of the pace of aging.” eLife 2022;11:e73420. PMID 35184856

[5] Corley MJ et al. “GLP-1 receptor agonist semaglutide associates with decelerated epigenetic aging in people with HIV.” Nature Communications 2026. PMID 40791720